
PCVX
Vaxcyte Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
37.000
Open
36.140
VWAP
36.14
Vol
1.09M
Mkt Cap
4.73B
Low
35.460
Amount
39.34M
EV/EBITDA(TTM)
--
Total Shares
108.80M
EV
3.05B
EV/OCF(TTM)
--
P/S(TTM)
--
Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.
Show More
6 Analyst Rating

157.30% Upside
Wall Street analysts forecast PCVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCVX is 94.25 USD with a low forecast of 65.00 USD and a high forecast of 137.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy

157.30% Upside
Current: 36.630

Low
65.00
Averages
94.25
High
137.00

157.30% Upside
Current: 36.630

Low
65.00
Averages
94.25
High
137.00
Mizuho
Salim Syed
Outperform
maintain
2025-06-21
Reason
Mizuho
Salim Syed
Price Target
2025-06-21
maintain
Outperform
Reason
Cantor Fitzgerald
Carter Gould
Buy
Initiates
n/a
2025-04-22
Reason
Cantor Fitzgerald
Carter Gould
Price Target
n/a
2025-04-22
Initiates
Buy
Reason
Cantor Fitzgerald analyst Carter Gould initiated coverage of Vaxcyte with an Overweight rating.
Needham
Joseph Stringer
Strong Buy
Reiterates
$90
2025-04-08
Reason
Needham
Joseph Stringer
Price Target
$90
2025-04-08
Reiterates
Strong Buy
Reason
Needham
Joseph Stringer
Strong Buy
Maintains
$140 → $90
2025-04-01
Reason
Needham
Joseph Stringer
Price Target
$140 → $90
2025-04-01
Maintains
Strong Buy
Reason
B of A Securities
Jason Gerberry
Strong Buy
Maintains
$157 → $137
2025-04-01
Reason
B of A Securities
Jason Gerberry
Price Target
$157 → $137
2025-04-01
Maintains
Strong Buy
Reason
Goldman Sachs
Chris Shibutani
Strong Buy
Maintains
$138 → $100
2025-04-01
Reason
Goldman Sachs
Chris Shibutani
Price Target
$138 → $100
2025-04-01
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Vaxcyte Inc (PCVX.O) is -7.37, compared to its 5-year average forward P/E of -12.77. For a more detailed relative valuation and DCF analysis to assess Vaxcyte Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-12.77
Current PE
-7.37
Overvalued PE
-8.45
Undervalued PE
-17.08
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-11.46
Current EV/EBITDA
-4.61
Overvalued EV/EBITDA
-5.98
Undervalued EV/EBITDA
-16.95
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
699.87
Current PS
0.00
Overvalued PS
1848.88
Undervalued PS
-449.13
Financials
Annual
Quarterly
FY2025Q1
YoY :
+58.11%
-180.79M
Operating Profit
FY2025Q1
YoY :
+48.09%
-140.72M
Net Income after Tax
FY2025Q1
YoY :
+22.35%
-1.04
EPS - Diluted
FY2025Q1
YoY :
+12.75%
-193.03M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
2.8M
USD
5
6-9
Months
9.0M
USD
12
0-12
Months
20.5M
USD
14
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
1.4M
Volume
3
6-9
Months
1.3M
Volume
4
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
7
6.2M
Volume
Months
6-9
7
3.2M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
32.5K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
3
24.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
2.8M
USD
5
6-9
Months
9.0M
USD
12
0-12
Months
20.5M
USD
14
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
PCVX News & Events
Events Timeline
2025-05-15 (ET)
2025-05-15
12:59:01
FDA head says vaccine framework being prepared

2025-05-07 (ET)
2025-05-07
16:09:02
Vaxcyte reports Q1 EPS ($1.04), consensus (98c)

2025-05-01 (ET)
2025-05-01
08:13:21
Vaxcyte appoints Brandicourt to board of directors

Sign Up For More Events
Sign Up For More Events
News
6.5
06-05NASDAQ.COMThe Math Shows ESML Can Go To $48
2.0
05-06NASDAQ.COMOversold Conditions For Vaxcyte (PCVX)
5.0
05-06SeekingAlphaVinay Prasad to head FDA division regulating vaccines
Sign Up For More News
People Also Watch

ESTC
Elastic NV
89.860
USD
+1.30%

AAON
Aaon Inc
83.370
USD
+7.49%

FOXA
Fox Corp
56.670
USD
+0.71%

ULS
UL Solutions Inc
70.330
USD
-0.44%

BG
Bunge Global SA
77.270
USD
+0.44%

MEDP
Medpace Holdings Inc
447.490
USD
-1.80%

PSO
Pearson PLC
14.310
USD
+0.35%

SBS
Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP
19.310
USD
-2.08%

BF.B
Brown-Forman Corp
30.960
USD
-0.61%

SKX
Skechers USA Inc
63.030
USD
-0.16%
FAQ

What is Vaxcyte Inc (PCVX) stock price today?
The current price of PCVX is 36.63 USD — it has increased 1.08 % in the last trading day.

What is Vaxcyte Inc (PCVX)'s business?

What is the price predicton of PCVX Stock?

What is Vaxcyte Inc (PCVX)'s revenue for the last quarter?

What is Vaxcyte Inc (PCVX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Vaxcyte Inc (PCVX)'s fundamentals?

How many employees does Vaxcyte Inc (PCVX). have?
